Santen Pharmaceutical has filed a patent for a pharmaceutical composition containing a specific compound to enhance preservation efficacy. The composition includes isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or its salt, along with edetic acid or its salt, aiming to improve stability. GlobalData’s report on Santen Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Santen Pharmaceutical Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Santen Pharmaceutical, Nanoparticle drug conjugates was a key innovation area identified from patents. Santen Pharmaceutical's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

The patent application (Publication Number: US20240024484A1) describes a method for stabilizing isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or its salt in a pharmaceutical composition. The stabilization is achieved by incorporating edetic acid or a salt thereof into the composition. Additionally, the method involves the use of a nonionic surfactant along with edetic acid to enhance the stability of the compound.

Furthermore, the patent application specifies the types of nonionic surfactants that can be used, such as polyoxyethylene castor oil, polyoxyethylene hardened castor oil, polyoxyethylene sorbitan fatty acid ester, or vitamin E TPGS. The content of the nonionic surfactant in the pharmaceutical composition ranges from 0.001 to 5% (w/v), with specific ranges provided for optimal stabilization. The composition may also include other additives like boric acid, citric acid, or acetic acid, but excludes sorbic acid. The pharmaceutical composition is intended for the prevention or treatment of glaucoma, ocular hypertension, or reduction of intraocular pressure, and is recommended to be stored in polyethylene containers for stability.

To know more about GlobalData’s detailed insights on Santen Pharmaceutical, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies